Windtree Therapeutics, Inc. announced that it has entered into a Common Stock Purchase Agreement with an equity line investor whereby the Company has the right, but not the obligation, to sell to the Purchaser, and the Purchaser is obligated to purchase newly issued shares of the Company?s common stock, par value $0.001 per share for the gross proceeds of up to $35,000,000 on June 26, 2024.